O
4.54
0.17 (3.89%)
| Previous Close | 4.37 |
| Open | 4.39 |
| Volume | 566,151 |
| Avg. Volume (3M) | 900,363 |
| Market Cap | 310,632,672 |
| Price / Book | 0.830 |
| 52 Weeks Range | |
| Earnings Date | 12 Aug 2025 |
| Diluted EPS (TTM) | -2.00 |
| Total Debt/Equity (MRQ) | 0.30% |
| Current Ratio (MRQ) | 15.22 |
| Operating Cash Flow (TTM) | -124.83 M |
| Levered Free Cash Flow (TTM) | -70.86 M |
| Return on Assets (TTM) | -27.44% |
| Return on Equity (TTM) | -41.59% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Olema Pharmaceuticals, Inc. | Bearish | Bearish |
AIStockmoo Score
1.0
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 1.00 |
|
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 3.32% |
| % Held by Institutions | 98.70% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 30.00 (HC Wainwright & Co., 560.79%) | Buy |
| Median | 22.00 (384.58%) | |
| Low | 18.00 (Goldman Sachs, 296.48%) | Buy |
| Average | 23.33 (413.88%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 4.63 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Goldman Sachs | 14 May 2025 | 18.00 (296.48%) | Buy | 4.50 |
| Oppenheimer | 14 May 2025 | 22.00 (384.58%) | Buy | 4.50 |
| HC Wainwright & Co. | 28 Apr 2025 | 30.00 (560.79%) | Buy | 4.89 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 02 Jul 2025 | Announcement | Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 03 Jun 2025 | Announcement | Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 28 May 2025 | Announcement | Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual Meeting |
| 21 May 2025 | Announcement | Olema Oncology to Participate in Upcoming Investor Conferences |
| 13 May 2025 | Announcement | Olema Oncology Reports First Quarter 2025 Financial and Operating Results |
| 09 May 2025 | Announcement | Olema Oncology to Participate in Upcoming Investor Conferences |
| 02 May 2025 | Announcement | Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 25 Apr 2025 | Announcement | Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |